Harrow (NASDAQ:HROW) Earns Buy Rating from HC Wainwright

Harrow (NASDAQ:HROW)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research report issued on Thursday,Benzinga reports. They presently have a $70.00 target price on the stock. HC Wainwright’s target price points to a potential upside of 110.34% from the company’s previous close.

HROW has been the topic of a number of other research reports. William Blair restated an “outperform” rating on shares of Harrow in a research note on Tuesday, March 3rd. Zacks Research downgraded Harrow from a “hold” rating to a “strong sell” rating in a research note on Tuesday, March 3rd. Cantor Fitzgerald lowered their price objective on Harrow from $94.00 to $91.00 and set an “overweight” rating for the company in a report on Wednesday, March 4th. Weiss Ratings restated a “sell (e+)” rating on shares of Harrow in a research note on Thursday, January 22nd. Finally, Nomura downgraded Harrow to a “neutral” rating in a report on Wednesday. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Harrow has a consensus rating of “Moderate Buy” and an average price target of $71.14.

Harrow Trading Down 3.3%

HROW opened at $33.28 on Thursday. Harrow has a 12-month low of $20.85 and a 12-month high of $54.85. The company has a debt-to-equity ratio of 4.67, a current ratio of 2.20 and a quick ratio of 2.06. The stock has a market capitalization of $1.24 billion, a PE ratio of -195.75 and a beta of 0.05. The firm’s fifty day moving average price is $44.53 and its 200 day moving average price is $43.45.

Institutional Investors Weigh In On Harrow

Several large investors have recently made changes to their positions in the company. Royal Bank of Canada boosted its position in shares of Harrow by 102.5% during the first quarter. Royal Bank of Canada now owns 9,813 shares of the company’s stock worth $261,000 after buying an additional 4,967 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Harrow by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,146 shares of the company’s stock valued at $483,000 after acquiring an additional 790 shares during the period. Strs Ohio bought a new stake in Harrow during the 1st quarter valued at $149,000. Geode Capital Management LLC raised its stake in Harrow by 4.7% during the 2nd quarter. Geode Capital Management LLC now owns 810,803 shares of the company’s stock valued at $24,765,000 after acquiring an additional 36,724 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey boosted its position in Harrow by 16.7% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 7,273 shares of the company’s stock worth $222,000 after acquiring an additional 1,041 shares during the period. Institutional investors and hedge funds own 72.76% of the company’s stock.

Harrow Company Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.